Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies
Priscilla K Brastianos, Franziska Maria Ippen, Umbreen Hafeez, Hui K Gan
ONCOLOGIST | WILEY | Published : 2018
Primary and metastatic tumors of the central nervous system present a difficult clinical challenge, and they are a common cause of disease progression and death. For most patients, treatment consists primarily of surgery and/or radiotherapy. In recent years, systemic therapies have become available or are under investigation for patients whose tumors are driven by specific genetic alterations, and some of these targeted treatments have been associated with dramatic improvements in extracranial and intracranial disease control and survival. However, the success of other systemic therapies has been hindered by inadequate penetration of the drug into the brain parenchyma. Advances in molecular ..View full abstract
We thank Nick Cianciola, Ph.D., of The Lockwood Group (Stamford, Connecticut, USA), and Ken Scholtz, Ph.D., for providing medical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines and funded by Ignyta (San Diego, California, USA).